Literature DB >> 21204910

Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.

Alex Bogason1, Angelica L Quartino, Pierre Lafolie, Michèle Masquelier, Mats O Karlsson, Christer Paul, Astrid Gruber, Sigurd Vitols.   

Abstract

AIMS: It has been shown that the cellular uptake and cytotoxicity of anthracyclines decrease with increasing cell density in vitro, an event termed 'the inocculum effect'. It is not known whether such an effect occurs in vivo. In this study the relationships between white blood cell (WBC) count, plasma and cellular concentrations of daunorubicin (DNR) in patients with acute myeloid leukaemia were investigated.
METHODS: Plasma and mononuclear blood cells were isolated from peripheral blood from 40 patients with acute myeloid leukaemia at end of infusion (time 1 h), 5 and 24 h following the first DNR infusion. DNR concentrations were determined by high-pressure liquid chromatography and related to the WBC count at diagnosis. A population pharmacokinetic model was used to estimate the correlations between baseline WBC count, volume of distribution and clearance of DNR.
RESULTS: A clear but weak inverse relationship between the baseline WBC count and plasma concentrations of DNR (r(2)=0.11, P<0.05) at time 1 was found. Furthermore, a clear relationship between baseline WBC count and DNR central volume of distribution using population pharmacokinetic modelling (dOFV 4.77, P<0.05) was also noted. Analysis of plasma DNR and the metabolite daunorubicinol (DOL) concentrations in patients with a high WBC count support that the low DNR/DOL concentrations are due a distribution effect.
CONCLUSION: This study shows that the leukaemic cell burden influences the plasma concentrations of anthracyclines. Further studies are needed to explore if patients with high a WBC count may require higher doses of anthracyclines.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21204910      PMCID: PMC3080638          DOI: 10.1111/j.1365-2125.2010.03894.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.

Authors:  U Tidefelt; J Liliemark; A Gruber; E Liliemark; B Sundman-Engberg; G Juliusson; L Stenke; A Elmhorn-Rosenborg; L Möllgård; S Lehman; D Xu; A Covelli; B Gustavsson; C Paul
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

3.  Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia.

Authors:  J P Matthews; J F Bishop; G A Young; S K Juneja; R M Lowenthal; O M Garson; R G Cobcroft; A J Dodds; A Enno; E A Gillett; R P Hermann; D E Joshua; D D Ma; J Szer; K M Taylor; M Wolf; K F Bradstock
Journal:  Br J Haematol       Date:  2001-06       Impact factor: 6.998

4.  Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study.

Authors:  B-M Frost; S Eksborg; O Björk; J Abrahamsson; M Behrendtz; A Castor; E Forestier; G Lönnerholm
Journal:  Med Pediatr Oncol       Date:  2002-05

5.  Drastic effect of cell density on the cytotoxicity of daunorubicin and cytosine arabinoside.

Authors:  Michèle Masquelier; Sigurd Vitols
Journal:  Biochem Pharmacol       Date:  2004-05-01       Impact factor: 5.858

6.  Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy.

Authors:  N Boissel; J M Cayuela; C Preudhomme; X Thomas; N Grardel; X Fund; I Tigaud; E Raffoux; P Rousselot; F Sigaux; L Degos; S Castaigne; P Fenaux; H Dombret
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

Review 7.  Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.

Authors:  Romano Danesi; Stefano Fogli; Alessandra Gennari; Pierfranco Conte; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.

Authors:  N Novitzky; V Thomas; L Abrahams; C du Toit; A McDonald
Journal:  Am J Hematol       Date:  2004-08       Impact factor: 10.047

9.  Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response.

Authors:  Alex Bogason; Hasanuzzaman Bhuiyan; Michèle Masquelier; Christer Paul; Astrid Gruber; Sigurd Vitols
Journal:  Eur J Clin Pharmacol       Date:  2009-10-10       Impact factor: 2.953

10.  Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979).

Authors:  Sophie Callies; Dinesh P de Alwis; Atul Mehta; Michael Burgess; Leon Aarons
Journal:  Cancer Chemother Pharmacol       Date:  2004-03-24       Impact factor: 3.333

View more
  10 in total

1.  Model-Based Residual Post-Processing for Residual Model Identification.

Authors:  Moustafa M A Ibrahim; Rikard Nordgren; Maria C Kjellsson; Mats O Karlsson
Journal:  AAPS J       Date:  2018-07-02       Impact factor: 4.009

Review 2.  Acute myeloid leukaemia: optimal management and recent developments.

Authors:  Luis Villela; Javier Bolaños-Meade
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

3.  Rewired metabolism in drug-resistant leukemia cells: a metabolic switch hallmarked by reduced dependence on exogenous glutamine.

Authors:  Claudia Stäubert; Hasanuzzaman Bhuiyan; Anna Lindahl; Oliver Jay Broom; Yafeng Zhu; Saiful Islam; Sten Linnarsson; Janne Lehtiö; Anders Nordström
Journal:  J Biol Chem       Date:  2015-02-19       Impact factor: 5.157

4.  Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.

Authors:  Savitha Varatharajan; John C Panetta; Ajay Abraham; Sreeja Karathedath; Ezhilpavai Mohanan; Kavitha M Lakshmi; Nancy Arthur; Vivi M Srivastava; Sandeep Nemani; Biju George; Alok Srivastava; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Cancer Chemother Pharmacol       Date:  2016-10-13       Impact factor: 3.333

5.  Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia.

Authors:  Zhen Huang; Juxiang Wang; Jiangchao Qian; Yuan Li; Zhisheng Xu; Min Chen; Hongfei Tong
Journal:  Mol Med Rep       Date:  2017-04-12       Impact factor: 2.952

6.  Loss of KDM6A confers drug resistance in acute myeloid leukemia.

Authors:  Sophie M Stief; Anna-Li Hanneforth; Sabrina Weser; Raphael Mattes; Michela Carlet; Wen-Hsin Liu; Michael D Bartoschek; Helena Domínguez Moreno; Matthias Oettle; Julia Kempf; Binje Vick; Bianka Ksienzyk; Belay Tizazu; Maja Rothenberg-Thurley; Hilmar Quentmeier; Wolfgang Hiddemann; Sebastian Vosberg; Philipp A Greif; Klaus H Metzeler; Gunnar Schotta; Sebastian Bultmann; Irmela Jeremias; Heinrich Leonhardt; Karsten Spiekermann
Journal:  Leukemia       Date:  2019-06-14       Impact factor: 11.528

7.  Variability Attribution for Automated Model Building.

Authors:  Moustafa M A Ibrahim; Rikard Nordgren; Maria C Kjellsson; Mats O Karlsson
Journal:  AAPS J       Date:  2019-03-08       Impact factor: 4.009

8.  Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial.

Authors:  Guillaume Drevin; Marie Briet; Caroline Bazzoli; Emmanuel Gyan; Aline Schmidt; Hervé Dombret; Corentin Orvain; Aurelien Giltat; Christian Recher; Norbert Ifrah; Philippe Guardiola; Mathilde Hunault-Berger; Chadi Abbara
Journal:  Pharmaceutics       Date:  2022-04-05       Impact factor: 6.321

9.  Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy.

Authors:  Branson Chen; Jong Bok Lee; Hyeonjeong Kang; Mark D Minden; Li Zhang
Journal:  J Exp Clin Cancer Res       Date:  2018-04-24

10.  An automated sampling importance resampling procedure for estimating parameter uncertainty.

Authors:  Anne-Gaëlle Dosne; Martin Bergstrand; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-09-08       Impact factor: 2.745

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.